At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed non-small cell lung cancer
- ✓Stage IIIB (locally advanced with malignant effusion) or Stage IV disease
- ✓No prior systemic therapy for NSCLC
- ✓Evidence of unidimensionally measurable disease
- ✕Prior systemic chemotherapy for lung cancer
- ✕History of or known brain metastases
- ✕NCI CTCAE Grade 3 hemorrhage within 4 weeks of study start
- ✕Evidence of hemoptysis within 4 weeks of study start
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study Of SU011248 As Consolidation Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating carboplatin, paclitaxel, and 1 other intervention for Non-small Cell Lung Cancer. Completed, enrolled 84 participants across 31 sites in 3 countries.
Detailed Summary
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).
Study Details
Timeline
Interventions
AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).